Kyverna Therapeutics, Inc. appointed Andrew Miller, Ph.D., and Sravan Emany as directors on February 24, 2026, following the resignation of Daniel Spiegelman on February 23, 2026. Dr. Miller brings experience from Karuna Therapeutics, with a prior $14 billion acquisition, while Mr. Emany is the CFO of Beam Therapeutics.